Oppenheimer Maintains Outperform on Edwards Lifesciences, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Edwards Lifesciences (EW) and raises the price target from $93 to $100.
March 18, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Edwards Lifesciences and raises the price target from $93 to $100.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100